Brief: Forte Biosciences, Inc. To Review The Second Quarter 2021 Results And Expects To Announce Topline Data From Phase 2 Clinical Trial Of FB-401 For The Treatment Of Atopic Dermatitis On Sept. 7
16/08/2021 21:51
Aug 16 (Reuters) - Forte Biosciences Inc FBRX.O :
* FORTE BIOSCIENCES, INC. TO REVIEW THE SECOND QUARTER 2021
RESULTS AND EXPECTS TO ANNOUNCE TOPLINE DATA FROM PHASE 2
CLINICAL TRIAL OF FB-401 FOR THE TREATMENT OF ATOPIC DERMATITIS
ON SEPT. 7
Source text for Eikon: ID:nBwbGF5fca
Further company coverage: FBRX.O
((Reuters.Briefs@thomsonreuters.com;))